王傳福:比亞迪半導體分拆上市目標未有改變
比亞迪(01211.HK)去年宣布終止分拆比亞迪半導體上市,被問到香港擬為特專科技公司設上市新規,會否考慮分拆此業務來港上市,董事長兼總裁王傳福強調比亞迪半導體上市計劃未曾改變,只是進度有調整所以叫停,指出由於公司汽車業務增長迅速,對半導體零部件需求變得龐大,因此令該業務獨立性變弱。
他笑言汽車業務不可能長時間維持高速增長,待回歸常態後便會伺機再推進分拆,惟上市地點尚未落實,會審視各地吸引力。
對於巴菲特旗下投資旗艦巴郡(BRK.A.US)近月多次減持公司股份,王傳福重申巴菲特是很重要的股東及支持者,股權變動屬股東自身權利,無論減持幅度是多少仍會感謝對方的支持。未來亦會做好自身經營,相信減持對公司影響較少。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.